Loomis, Sayles & Company
ARMP icon

Loomis, Sayles & Company’s Armata Pharmaceuticals ARMP Stock Holding History

Loomis, Sayles & Company’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-129,956
Closed -$621K – 834
2021
Q1 		$621K Buy
+129,956
New +$639K ﹤0.01% 491

Other funds holding ARMP

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
SF
Synovus Financial Columbus, Georgia $8.74B AUM 12.78% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company's ARMP Position: Q2 2021 in Review

Loomis, Sayles & Company sold out of Armata Pharmaceuticals (ARMP) in Q2 2021, closing a stake of 129,956 shares — an estimated $621K sold.

Loomis, Sayles & Company first reported a position in ARMP in Q1 2021 and held it in 1 quarter. The position peaked at $621K in Q1 2021. 21 funds tracked by Wall St. Rank hold ARMP as of Q2 2021.

  • Loomis, Sayles & Company reported no remaining Armata Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 129,956 Armata Pharmaceuticals shares in Q2 2021, an estimated $621K.
  • Loomis, Sayles & Company first reported a position in Armata Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Loomis, Sayles & Company's Armata Pharmaceuticals position peaked at $621K in Q1 2021.
  • 21 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q2 2021.

Based on Loomis, Sayles & Company's 13F filing for Q2 2021, filed 13 Aug 2021.